WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Banco BBVA has now made two tests of this key technical level in nearly three weeks....
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX....
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Boston Scientific (BSX) have performed compared to their sector so far this year....
The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question...
Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower....
Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflu...
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year....
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank...
First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '...